Search research articles
Contact Us
Filters
Showing results (91-100 of 117) with videos related to
Page
of 12
Sort By:
Journal of the American Society of Nephrology : JASN
|
July 24, 2012
Effects of phosphate binders in moderate CKD
Geoffrey A Block, David C Wheeler, Martha S Persky, et al.
Kidney International
|
January 28, 2005
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl
Sharon M Moe, Glenn M Chertow, Jack W Coburn, et al.
Kidney International Reports
|
April 30, 2025
Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD
Bernard Chan, Amanda Varghese, Sunil V Badve, et al.
JAMA
|
January 19, 2017
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials
Geoffrey A Block, David A Bushinsky, John Cunningham, et al.
JAMA Network Open
|
September 19, 2024
Acceptance of SARS-CoV-2 Surveillance Testing Among Patients Receiving Dialysis: A Cluster Randomized Trial
Maria Montez-Rath, Meri Varkila, Xue Yu, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 25, 2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Patrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, et al.
Journal of the American Society of Nephrology : JASN
|
December 16, 2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
Sharon M Moe, Safa Abdalla, Glenn M Chertow, et al.
Circulation
|
June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Sharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Journal of Diabetes and Its Complications
|
October 16, 2018
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease
Glenn M Chertow, Gerald B Appel, Geoffrey A Block, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview
Glenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 117) with videos related to
Sort By:
Page
of 12
Journal of the American Society of Nephrology : JASN
|
July 24, 2012
Effects of phosphate binders in moderate CKD
Geoffrey A Block, David C Wheeler, Martha S Persky, et al.
Kidney International
|
January 28, 2005
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl
Sharon M Moe, Glenn M Chertow, Jack W Coburn, et al.
Kidney International Reports
|
April 30, 2025
Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD
Bernard Chan, Amanda Varghese, Sunil V Badve, et al.
JAMA
|
January 19, 2017
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials
Geoffrey A Block, David A Bushinsky, John Cunningham, et al.
JAMA Network Open
|
September 19, 2024
Acceptance of SARS-CoV-2 Surveillance Testing Among Patients Receiving Dialysis: A Cluster Randomized Trial
Maria Montez-Rath, Meri Varkila, Xue Yu, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 25, 2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Patrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, et al.
Journal of the American Society of Nephrology : JASN
|
December 16, 2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
Sharon M Moe, Safa Abdalla, Glenn M Chertow, et al.
Circulation
|
June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Sharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Journal of Diabetes and Its Complications
|
October 16, 2018
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease
Glenn M Chertow, Gerald B Appel, Geoffrey A Block, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview
Glenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.
Page
of 12